Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent

NCT04349280 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04349280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04349280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
October 15, 2020
Completion date
August 15, 2022
Enrollment
25 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms